| Name | AU-15330 |
| Description | AU-15330 is a proteolytic targeting chimera (PROTAC) that simultaneously targets SMARCA4, SMARCA2, and PBRM1 for degradation and exhibits cytotoxicity in H3.3K27M cells but not in H3 wild-type cells. [2] |
| In vitro | METHODS: PCa cells (LNCaP, VCaP, 22RV1, and LAPC4) were treated with different concentrations of AU-15330 (0.1, 1 μM).
RESULTS AU-15330 attenuated the growth of these cells and induced apoptotic cell death, while having no antiproliferative effect on benign or non-neoplastic prostate cells. [1] |
| In vivo | METHODS: AU-15330 (60 mg kg, i.v.) was administered to mice bearing VCaP and C4-2B castration-resistant tumor models, 3 days per week.
RESULTS AU-15330 inhibited tumor growth in mice bearing VCaP and C4-2B castration-resistant tumor models without significant toxicity. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 126.0 mg/mL (166.7 mM), Sonication is recommended.
|
| Keywords | AU-15330 | AU15330 | AU 15330 |
| Inhibitors Related | ABBV-744 | CeMMEC1 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | ARV-471 | Curcumin | dBET6 | Naphthol AS-E | Bisdemethoxycurcumin |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
